Publications by authors named "Jayendar Kumar Krishnaswamy"
Dermatol Ther (Heidelb)
March 2022
Article Synopsis
- Nemolizumab is a monoclonal antibody effective in treating moderate to severe atopic dermatitis (AD) in adolescents, targeting interleukin-31 receptors to alleviate symptoms.
- In a 16-week open-label study, 20 adolescents (ages 12-17) received nemolizumab, showing significant improvements in rash severity, itching, and sleep disturbances.
- Pharmacokinetic analysis revealed a stable one-compartment model with a mean half-life of around 16.7 days, and treatment effects were consistent with results in adults, with body weight being the main variable influencing drug levels.
